These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 26510455)

  • 1. Immune checkpoints and immunotherapy for colorectal cancer.
    Singh PP; Sharma PK; Krishnan G; Lockhart AC
    Gastroenterol Rep (Oxf); 2015 Nov; 3(4):289-97. PubMed ID: 26510455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the Verge: Immunotherapy for Colorectal Carcinoma.
    Oh DY; Venook AP; Fong L
    J Natl Compr Canc Netw; 2015 Aug; 13(8):970-8. PubMed ID: 26285242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors for immunotherapy in melanoma.
    Teixidó C; González-Cao M; Karachaliou N; Rosell R
    Ann Transl Med; 2015 Sep; 3(15):208. PubMed ID: 26488004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results and challenges of immune checkpoint inhibitors in colorectal cancer.
    Emambux S; Tachon G; Junca A; Tougeron D
    Expert Opin Biol Ther; 2018 May; 18(5):561-573. PubMed ID: 29471676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emerging role of immunotherapy in colorectal cancer.
    Lynch D; Murphy A
    Ann Transl Med; 2016 Aug; 4(16):305. PubMed ID: 27668225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential role of immunotherapy to treat colorectal cancer.
    Amin M; Lockhart AC
    Expert Opin Investig Drugs; 2015 Mar; 24(3):329-44. PubMed ID: 25519074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
    Farina MS; Lundgren KT; Bellmunt J
    Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma.
    Shao Z; Wang AZ; George DJ; Zhang T
    Asian J Urol; 2016 Oct; 3(4):268-277. PubMed ID: 29264195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current status and prognosis of immune checkpoint inhibitors for esophageal cancer].
    Gao HJ; Shang XB; Yu ZT
    Zhonghua Wai Ke Za Zhi; 2019 Oct; 57(10):77-82. PubMed ID: 31510736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway.
    Momtaz P; Postow MA
    Pharmgenomics Pers Med; 2014; 7():357-65. PubMed ID: 25484597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy.
    Rotte A; Jin JY; Lemaire V
    Ann Oncol; 2018 Jan; 29(1):71-83. PubMed ID: 29069302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer.
    Winer A; Ghatalia P; Bubes N; Anari F; Varshavsky A; Kasireddy V; Liu Y; El-Deiry WS
    Oncologist; 2019 Nov; 24(11):1416-1419. PubMed ID: 31444293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer immunology - development of novel anti-cancer therapies.
    Rothschild SI; Thommen DS; Moersig W; Müller P; Zippelius A
    Swiss Med Wkly; 2015; 145():w14066. PubMed ID: 25668078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
    Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
    Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of immune checkpoint inhibitor in colorectal cancer].
    Kitano S
    Nihon Rinsho; 2016 Nov; 74(11):1818-1820. PubMed ID: 30550688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitors for metastatic bladder cancer.
    Massari F; Di Nunno V; Cubelli M; Santoni M; Fiorentino M; Montironi R; Cheng L; Lopez-Beltran A; Battelli N; Ardizzoni A
    Cancer Treat Rev; 2018 Mar; 64():11-20. PubMed ID: 29407369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.